Csenge Advisory Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Csenge Advisory Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,885	Closed	-$360K	–	348
2019 Q4	$360K	Buy	+7,885	New	+$313K	0.09%	205

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

FMP

Financial Management Professionals Austin, Texas $1.05B AUM 21.07% 1-Year Est. Return

BCM

Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Csenge Advisory Group's XPH Position: Q1 2020 in Review

Csenge Advisory Group sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2020, closing a stake of 7,885 shares — an estimated $360K sold.

Csenge Advisory Group first reported a position in XPH in Q4 2019 and held it in 1 quarter. The position peaked at $360K in Q4 2019. 66 funds tracked by Wall St. Rank hold XPH as of Q1 2020.

Csenge Advisory Group reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2020 after selling out during the quarter.
Csenge Advisory Group sold 7,885 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2020, an estimated $360K.
Csenge Advisory Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2019 and held it in 1 quarter.
Csenge Advisory Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $360K in Q4 2019.
66 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2020.

Based on Csenge Advisory Group's 13F filing for Q1 2020, filed 21 Apr 2020.